Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13483797 | 1.00 | KCNH2 (0.32) | KCNH2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL13952157 | 1.00 | KCNH2 (0.32) | KCNH2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL13483821 | 1.00 | KCNH2 (0.32) | KCNH2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL13930441 | 1.00 | KCNH2 (0.32) | KCNH2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL5258982 | 0.88 | CHRM2 (0.31) | KCNH2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL5956115 | 0.83 | GBA1 (0.33) | KCNH2SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL13931104 | 0.83 | — | — | |
| SCHEMBL28520597 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL458312 | 0.81 | GBA1 (0.41) | KCNH2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL13483787 | 0.81 | KCNH2 (0.38) | KCNH2CHRM1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3312160-A1 | HEPATITIS B ANTIVIRAL AGENTS | Novira Therapeutics Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
| US-9751857-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150259324-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9066932-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9061008-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | NOVIRA THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8629274-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| EP-0705258-B1 | AZOLYL-CYCLIC AMINE DERIVATIVES WITH IMMUNOMODULATORY ACTIVITY | KNOLL AG (DE) | 1998-12-30 | — | — | EP | disclosed |
| US-5741800-A | ANTIINFLAMMATORY AGENT, ANTIALLERGENS | KNOLL AKTIENGESELLACHAFT (DE) | 1998-04-21 | — | — | US | disclosed |
| EP-0705258-A1 | AZOLYL-CYCLIC AMINE DERIVATIVES WITH IMMUNOMODULATORY ACTIVITY | Knoll AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000507-A1 | AZOLYL-CYCLIC AMINE DERIVATIVES WITH IMMUNOMODULATORY ACTIVITY | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152073-A1 | Hepatitis B Antiviral Agents | HAVCR2, EIF2AK2, IRF3 | KCNH2 4676/4885CHRM1 4666/4885CHRM3 4478/4885 |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | KCNH2 4676/4885CHRM1 4666/4885CHRM3 4478/4885 |
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | KCNH2 4676/4885CHRM1 4666/4885CHRM3 4478/4885 |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | KCNH2 4676/4885CHRM1 4666/4885CHRM3 4478/4885 |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | KCNH2 4676/4885CHRM1 4666/4885CHRM3 4478/4885 |
| US-20150259324-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | KCNH2 4676/4885CHRM1 4666/4885CHRM3 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.